| Catalog No. |
Size |
Price |
Figures |
|---|
Z02191-10 ug
| 10 ug | $ 130.00 | |
|---|
Z02191-50 ug
| 50 ug | $ 800.00 |
|---|
Z02191-1 mg
| 1 mg | $ 3250.00 |
|---|
| Full Name | | Long Arg3 Insulin-like Growth Factor-I (Long-R3-IGF-I) (Media Grade), human |
|
| Abbreviated Name-1 | Long Arg3 Insulin-like Growth Factor-I (Long-R3-IGF-I) (Media Grade), human;Long-R3-IGF-I |
|---|
| Description | Human Long Arg3 Insulin-like Growth Factor-I (Long-R3-IGF-I) is an 83 amino acid analog of human IGF-I comprising the complete human IGF-I sequence with the substitution of an Arg for the Glu at position 3 (hence R3), and a 13 amino acid extension peptide at the N-terminus. Scientists have engineered this analog with the express purpose of increasing biological activity. Human Long-R3-IGF-I is significantly more potent than human IGF-I in vitro. The enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.
GenScript Long Arg3 Insulin-like Growth Factor-I (Long-R3-IGF-I) (Media Grade), human, produced in E. coli, is a single, non-glycosylated, polypeptide chain containing 83 amino acids and having a molecular mass of 9,111 Da. |
|---|
| Source | E. coli |
|---|
| M.W. | 9,111 Da |
|---|
| Purity | The purity of GenScript Recombinant Human Long-R3-IGF-I is greater than 95% as determined by the following methods:
(a) RP-HPLC analysis
(b) Reducing and non-reducing SDS-PAGE silver-stained gel analysis |
|---|
| Endotoxin Level | The endotoxin level of GenScript Recombinant Human Long-R3-IGF-I is below 0.1 ng/μg (1 IEU/μg) of Long-R3-IGF-I. |
|---|
| Storage | Although GenScript lyophilized Long-R3-IGF-I remain stable at room temperature for three weeks, it is best stored desiccated below -18°C. After reconstitution, GenScript Long-R3-IGF-I may be stored at 4°C for up to seven days and below -18°C for longer periods. For long-term storage, it is recommended that a carrier protein (0.1% HSA or BSA) be added. Please avoid freeze-thaw cycles. |
|---|
| Formulation | Long-R3-IGF-I is lyophilized after extensive dialysis against acetic acid buffer. |
|---|
| Reconstitution | It is recommended that the lyophilized GenScript Long-R3-IGF-I be reconstituted in 500 mM acetic acid not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. |
|---|
| Specificity | The ED50 of GenScript Long-R3-IGF-I, calculated by the dose-dependant proliferation of murine BALBC 3T3 cells, is less than 1.0 ng/ml, corresponding to a specific activity of 1.0×106 IU/mg. For most in vitro applications, GenScript Long-R3-IGF-I exerts its biological activity in the concentration range of 0.2-20 ng/ml. |
|---|
| Sequence | The sequence of the first five N-terminal amino acids has been found to be Met-Phe-Pro-Ala-Met. |
|---|
